DXB (ASX) Ann: AGM Presentation

Originally posted by vintage: ↑

Your attempts to spread negative innuendo are going from bad to worse - ill-informed and half-baked at best.

Your comments re Advanz are ridiculous for 2 reasons. One is that big pharmas are successful because they are astute and prudent and do not sloppily 'give away' $10M on a wing and a prayer. They have tight due diligence protocols and it is these protocols - 'not suck it and see and who cares if we blow $10M' - that determine their investments. Secondly, due to the agreed milestones, they have far more exposure than the $10M, if those milestones are met.

Your comments re the data are equally absurd. It is not 'having data' that is important. Its how you interpret it and how you calculate the economic and health benefits implicit in the data. Advanz have an army of scientists, medicos and promotional experts at their disposal - resources you could only dream about. They have voted with their feet. You haven't. That is your right but I know whose path I prefer.

Next, your aspersions against the management for not publishing the p-values and standard errors are just plain wrong. They are provided in multiple announcements - including those on 24 Feb 2022 and 29 Mar 2022 and in the presentation at the Bio International Convention 6 June 2023.

Finally, getting your nickers in a knot over the p-values and standard errors is a red herring. You don't have to be Einstein to know that a small sample (as in most Phase 1 and 2 trials) is going to have very high p-values and standard errors. But that is irrelevant. Phase 2 studies are for determining 'safety' and çlinical significance', not statistical significance. That is what Phase 3 is for - to demonstrate BOTH clinical and statistical significance.

The beauty of the Phase 2a trial was that it demonstrated both clinical significance and safety. We know the drug works - and by how much it works on a statistically insignificant'' population of 7. What we now need to know, is will it work as well - if not better - on a statistically significant'' population of 74.

And remember, 'statistical significance' is not a positive in and of itself. It is quite possible, for instance, to have very low p-value (i.e. high statistical significance) for clinical benefits that are negligible and not even worth pursuing.

You need both proofs - clinical and statistical - but it is a red herring to say you need the latter in Phase 2. If you had it, in effect, you would not need Phase 3.

Expand

Great post.

The poster you responding to is clearly a downramper.

Its not that we don't value other side of the coin, but comments like this "I'm aware of for this asset is their diabetes kidney disease study, but I read that flopped" clearly shows misrepresentation of facts.

On the basis of the "Flopped" DKD trial, Dimerix announced that it has entered into an agreement with the Australian Centre for Accelerating Diabetes Innovation (ACADI) to commence a clinical trial on diabetic kidney disease (expected to commence Q4 this year).

The reason it hasn't progressed coz Dimerix is fully focused on FSGS...I am sure we will hear about DKD and COPD in due course...

No.	Vol.	Price($)
1	136	52.5¢

No.

Vol.

Price($)

136

52.5¢

Price($)	Vol.	No.
53.5¢	28650	2

Price($)

Vol.

No.

53.5¢

28650

No.	Vol.	Price($)
1	136	0.525
2	414653	0.520
5	523978	0.515
10	583975	0.510
7	72242	0.505

No.

Vol.

Price($)

136

0.525

414653

0.520

523978

0.515

583975

0.510

72242

0.505

Price($)	Vol.	No.
0.535	28650	2
0.540	48239	2
0.545	39073	3
0.550	304563	12
0.555	70960	3

Price($)

Vol.

No.

0.535

28650

0.540

48239

0.545

39073

0.550

304563

0.555

70960

(20min delay)
Last 52.5¢		Change -0.015(2.78%)		Mkt cap ! $288.8M

Open	High	Low	Value	Volume
53.0¢	54.0¢	51.0¢	$1.930M	3.666M

Ann: AGM Presentation, page-62

Evolution shares up 3% on quarterly results for June showing rise in gold production

Noronex joins forces with South32 to look for copper in Namibia

Talking Australia's very competitive property landscape: Realty Talks

AI stocks: What to expect in 2024-25

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: AGM Presentation, page-62

Top Stories

Evolution shares up 3% on quarterly results for June showing rise in gold production

Noronex joins forces with South32 to look for copper in Namibia

Talking Australia's very competitive property landscape: Realty Talks

AI stocks: What to expect in 2024-25

Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News